Crossmark Global Holdings Inc. Purchases 155,795 Shares of Takeda Pharmaceutical Company Limited (NYSE:TAK)

Crossmark Global Holdings Inc. lifted its position in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK) by 284.9% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 210,484 shares of the company’s stock after buying an additional 155,795 shares during the period. Crossmark Global Holdings Inc.’s holdings in Takeda Pharmaceutical were worth $2,787,000 as of its most recent SEC filing.

A number of other hedge funds also recently bought and sold shares of the company. Versant Capital Management Inc purchased a new position in shares of Takeda Pharmaceutical during the fourth quarter worth approximately $26,000. Wilmington Savings Fund Society FSB purchased a new position in Takeda Pharmaceutical in the 3rd quarter worth $40,000. EverSource Wealth Advisors LLC lifted its stake in Takeda Pharmaceutical by 38.6% in the second quarter. EverSource Wealth Advisors LLC now owns 3,082 shares of the company’s stock worth $43,000 after purchasing an additional 859 shares during the last quarter. BNP Paribas Financial Markets boosted its position in Takeda Pharmaceutical by 416.0% during the third quarter. BNP Paribas Financial Markets now owns 3,220 shares of the company’s stock valued at $46,000 after buying an additional 2,596 shares during the period. Finally, Smithfield Trust Co grew its stake in shares of Takeda Pharmaceutical by 76.9% during the third quarter. Smithfield Trust Co now owns 3,428 shares of the company’s stock valued at $49,000 after buying an additional 1,490 shares during the last quarter. Institutional investors own 9.17% of the company’s stock.

Takeda Pharmaceutical Trading Down 1.5 %

NYSE TAK opened at $12.91 on Thursday. The firm has a market cap of $41.06 billion, a PE ratio of 22.25, a price-to-earnings-growth ratio of 0.23 and a beta of 0.51. Takeda Pharmaceutical Company Limited has a 1-year low of $12.57 and a 1-year high of $15.08. The stock has a 50-day moving average of $13.35 and a 200-day moving average of $13.90. The company has a current ratio of 1.28, a quick ratio of 0.77 and a debt-to-equity ratio of 0.64.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.